Comparable to the 2020 resolution, Novartis AG’s $25 million 2016 civil resolution with the SEC anxious poor sponsorships of HCPs to conferences and inappropriate payments to HCPs to collect “health care info.” The reality that Novartis is currently dealing with a considerably larger sized—and felony—resolution for identical misconduct sh